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Abstract
Background: Male breast cancer (MBC) is a rare disease representing less than 1% of all malignancies in men and
only 1% of all incident breast cancers. Our study details clinico-pathological features, treatments and prognostic
factors in a large Moroccan cohort.
Findings: One hundred and twenty-seven patients were collected from 1985 to 2007 at the National Institute of
Oncology in Rabat, Morocco.
Median age was 62 years and median time for consultation 28 months. The main clinical complaint was a mass
beneath the areola in 93, 5% of the cases. Most patients have an advanced disease. Ninety-one percent of tumors
were ductal carcinomas.
Management consisted especially of radical mastectomy; followed by adjuvant radiotherapy and hormonal therapy
with or without chemotherapy. The median of follow-up was 30 months. The evolution has been characterized by
local recurrence; in twenty two cases (17% of all patients). Metastasis occurred in 41 cases (32% of all patients). The
site of metastasis was the bone in twenty cases; lung in twelve cases; liver in seven case; liver and skin in one case
and pleura and skin in one case.
Conclusion: Male breast cancer has many similarities to breast cancer in women, but there are distinct features
that should be appreciated. Future research for better understanding of this disease at national or international
level are needed to improve the management and prognosis of male patients.
Background
Male breast cancer is a rare disease that accounts for
less than 1% of all cancers in men and less than 1% of
all diagnosed breast cancers [1]. The literature regarding
male breast cancer consists mainly of retrospective stu-
dies, and there are no randomized prospective data for
this disease. This is an entity for which optimum man-
agement and treatment guidelines are not clearly estab-
lished. Generally, treatment recommendations have been
extrapolated from results of trials in female patients.
In this study, we retrospectively evaluated the clinico-
pathological features, treatments and the results
obtained in 127 cases of male breast cancer treated at
the National Institute of Oncology in Rabat, Morocco,
between 1985 and 2007.
Patients and methods
Clinical data
The investigation was a retrospective (the data was col-
lected by chart review), observational, single-centre
study.
Inclusion criteria were: male patients > 18 years old
with localized, locally Advanced or metastatic breast
cancer.
We excluded from the study patients who had not fol-
low up after initial diagnosis.
Breast carcinoma diagnosis was made by biopsy of the
breast tumor. Tumor staging was carried out according
to the TNM classification 2002 modified in 2003. Histo-
logical tumor grading was performed using the Scarff
Bloom and Richardson (SBR) histological system.
Immunohistochemical analysis to determine estrogen
(ER) and progesterone receptor (PR) status was per-
formed using standard procedures on 4-μms e c t i o n so f
paraffinembedded tissue specimens stained with the
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respectively.
Nuclear staining 10% was considered a positive result.
Statistical analysis
Descriptive of clinical data were expressed in percentage
or median or mean ± SD. Survival was estimated by the
Kaplan Meier method, and compared by the log rank
test. The relationship between each of the explanatory
variables and outcome (EFS and OS) was assessed in
turn using univariate and multivariate Cox’s regression
analysis. A p value of < 0.05 was considered significant.
Consent and statement of ethical approval
As the treatment of each patient was decided by the
medical staff of the centre, oral consent was obtained
from the subjects and was approved by the institutional
review boards of the National Institute of Oncology,
Cancer Centre in Rabat. This study was approved by the
institutional review boards of National Institute of
Oncology, in Rabat.
Results
Clinical characteristics
One hundred and twenty-seven patients at the National
Institute of Oncology in Rabat, Morocco with a diagno-
sis of breast cancer between January 1985 and Decem-
ber 2007 were analyzed retrospectively and evaluated in
terms of general characteristics and survival.
The median age was 62 years (range 32-91 years). A
family history of breast cancer was noted in four cases.
The main clinical complaint was a mass beneath the
areola in 93, 5% of the cases. The tumor was associated
with gynecomastia in 4% of cases. Paget’sd i s e a s ew a s
found in 2, 5% of cases. The median time for consulta-
tion was 28 months (range: 3-48 months).
According to the TNM classification, tumors were
categorized as T1: 6 cases (5%), T2: 18 (14%), T4 and T3
in, respectively, 62, 5% and 17% of the cases and Tx
(unclassified tumors): 2 cases (1, 5%). Tumors were
classed as N1 and N2, respectively, in 55, 2% and 25, 2%
of the cases. Thirty seven patients (29%) initially had
metastases. Table 1 resumes clinico-pathological features.
Ductal infiltrating carcinoma (IDC) corresponded to
122 cases (96%), infiltrating ductal carcinoma with
Paget’s disease of the nipple in two cases and Invasive
lobular carcinoma (ILC) in one case.
According to the Scarff-Bloom-Richardson grading,
grade II or III was predominant (82% of the cases). Axil-
lary lymph nodes contained metastasis (N+) in 64, 5% of
the cases (54 patients).
Moreover, hormone receptors were evaluable in sixty
one cases. Both Estrogen receptor (ER) and progester-
one receptor (PR) were positive in 64% (39 patients).
Treatment
The treatment consisted of radical mastectomy (RM) in
71% (90 cases); modified radical mastectomy (MRM) in
seven cases; total mastectomy without axillary node dissec-
tion (AD) in seven cases and lumpectomy (L) in one case.
All patients received adjuvant therapy following sur-
gery. Sixty patients of ninty patients received radiother-
apy; the median delivered doses were 50 Gy to breast,
chest wall and regional lymph nodes. Chemotherapy (an
anthracycline-based protocol; AC60 or FEC 100) was
given in neoadjuvant situation in five cases, in adjuvant
situation in 23 cases. Chemotherapy delivery increased
according particularly to advanced stage and axillary
nodal involvement. Nine cases receive it in palliative
situation.
Hormonal therapy was delivered to fifty-seven patients
as adjuvant situation: Tamoxifen alone in 50 cases,
Table 1 Clinico-pathological features
0- 49 20 cases 16%
50-59 35 27,5%
Age (years) 60-69 50 39%
> 70 22 17,5%
Mass beneath the areola 119 cases 93,5%
Clinical complaint Gynecomastia 5 4%
Paget’disease 3 2,5%
Tx 2 cases 1,5%
T1 6 5%
Primary Tumor T2 18 14%
T3 22 17%
T4 79 62,5%
Nx 9 7,1%
Lymph node N0 16 12,5%
N1 70 55,2%
N2 32 25,2%
Metastasis M0 90 71%
M1 37 29%
I6 5 %
IIA 8 6,1
Stage IIB 12 9,6
III 64 50,3%
IV 37 29%
IDC: 122 96%
SBR 2 ou 3 100 82%
Histology With Paget’s disaese 2 1,6%
ILC 1 0,8%
ND 2 1,6%
Lymph node status pN0 29 35,5%
pN+ 54 64,5%
Hormone receptors RE 39/61 64%
RP 39/61 64%
Ductal infiltrating carcinoma (IDC); Invasive lobular carcinoma (ILC); not
defined (ND) Estrogen receptor (ER); progesterone receptor (PR).
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Page 2 of 5Tamoxifen with orchidectomy in four cases and castra-
tion in three cases. Seventeen patients received it in pal-
liative situation. Table 2 summarize the treatment
modalities according to the TNM stage
During the median follow-up period of 30 months (3-
168 months); the evolution has been characterized by
local recurrence in twenty two cases (17% of all
patients). Metastasis occurred in 41 cases (32% of all
patients). The site of metastasis was the bone in twenty
cases; lung in twelve cases; liver in seven case; liver and
skin in one case and pleura and skin in one case.
The 5- and 10-year overall survival (OS) rates were
63% and 55%. (Figure 1)
Discussion
Carcinoma of the male breast has many similarities to
breast cancer in women, but there are distinct features
that should be appreciated. During the last few years,
there has been an increase in the incidence of this dis-
ease. Review of Surveillance, Epidemiology and End
Result (SEER) data indicate a rise in the incidence of
male breast cancer, from 1.0 per 100,000 men in the
late 1970s to 1.2 per 100,000 men from 2000 to 2004
[1,2].
The mean age at diagnosis for men with breast cancer
is 67 years, which is approximately 5-10 years older
than the average age at diagnosis for women [1,3]. The
mean age in our patients (62 years) is lower than other
series.
Male breast cancer is likely to be caused by the con-
current effects of different risk factors, including clinical
disorders relating to hormonal imbalances, certain occu-
pational and environmental exposures, and genetic risk
factors, for instance a positive family history of breast
cancer and mutations in breast cancer predisposing
genes, such as BRCA genes, and possibly others [3].
The most common clinical sign of breast cancer onset
in men is a painless palpable retroareolar lump [4].
Other initial symptoms may include nipple involvement,
with retraction and/or ulceration and/or bleeding, axil-
lary lymphoadenopathies and gynecomastia [3,4].
As male breast does not have lobular elements, the
most frequently encountered male breast cancer type is
invasive ductal carcinoma (IDC) (85-95%) [4,5]. The
result in our study was similar with a ratio of 96% for
IDC and this was significantly higher than the other his-
tological types. Lobular carcinoma in situ, Paget disease
and inflammatory breast cancer have been rarely
described in men[5].
Positivity rate of receptors is more frequent in men
with breast cancer, in comparison to women [6]. In dif-
ferent studies, ER and PR positivity was reported as 75
to 93% [7,8]. In our study, both Estrogen receptor (ER)
and progesterone receptor (PR) were positive in 64%.
Breast cancer in men should be treated with the same
strategy as in women [9,10]. The most common surgical
procedure is modified radical mastectomy with axillary
node dissection [11]. However, recent studies are in favor
of modified radical or simple mastectomy combined with
radiation therapy. Postoperative radiotherapy does
achieve local control but no effect is observed on survival
[12]. In men treated with mastectomy, adjuvant radio-
therapy has shown to decrease local recurrence [13].
Table 2 Treatment modalities according to the TNM
stage
Surgery 6 cases
Stage I
(nb = 6)
Adjuvant 5 total mastectomy without AD, 1
(L)
Treatment 0
Surgery 8 cases
Stage II
A
(nb = 8)
2 total mastectomy without AD, 6
MRM
Chemotherapy 0
Radiation
therapy
0
Hormonal
therapy
0
Surgery 12
cases
Stage
IIB
(n = 12)
1 MRM, 11 RM
Chemotherapy 3
Radiation
therapy
8
Hormonal
therapy
6
Surgery 64
cases
Stage III
(n = 64)
59 RM immediatly
5 RM after neoadj CMT
neoadjuvant
CMT
5
adjuvant CMT 20
adjuvant RTH 52
adjuvant HT 51
Surgery 15
cases
Stage IV
(n = 37)
15 RM
CMT 9
RTH 9
10(bone’metastasis)
HT 17
BSC 11
Lumpectomy (L); modified radical mastectomy (MRM); radical mastectomy
(RM); axillary dissection (AD); Chemotherapy (CMT); Radiation therapy (RT);
Hormonal therapy (HT); Best supportive care (BSC).
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Page 3 of 5Tamoxifen has proved to lead to an increase in survi-
val rates in women with hormone-responsive disease
and to date is generally considered the standard adju-
vant treatment for hormone-dependent male breast can-
cer [14]. The tolerance of the drug has not been
sufficiently studied in men; its main side effects are deep
venous thrombosis, reduction of libido, impotence,
mood changes and hot flushes [15].
Chemotherapy should be used in the absence or doubt
about endocrine-responsiveness. Frequently used che-
motherapy regimens were CMF, FEC and EC [16]. The
taxanes may be considered when lymph nodes are
involved. Regarding the use of adjuvant trastuzumab,
since no specific data exist, its use should be considered
according to patients’ and tumor characteristics [17,18].
The overall 5- and 10-year survival rate of male breast
cancer patients are around 60 and 40%, respectively
[17]. The number of histologically positive axillary
nodes and the tumor size are significant prognostic fac-
tors. Another negative prognostic factor is the advanced
age at the time of diagnosis, since the increased pre-
sence of comorbidities may limit the possibility of treat-
ment [18].
Conclusion
Lifetime in men with breast cancer is worse than in
w o m e n .W h i l es o m ei n v e s t i g a t o r se x p l a i nt h i sw i t h
more aggressive biologic behavior of male breast cancer,
more frequent explanation is the rareness of male breast
cancer and achieving its diagnosis at a more advanced
stage.
Without a concerted effort, the literature pertaining to
male breast cancer will remain a collection of retrospec-
tive series and pilot studies. Efforts to develop rando-
mized, prospective studies within cooperative groups
and other clinical trial consortia are essential.
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